La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
41 hedge funds and large institutions have $53.9M invested in La Jolla Pharmaceutical Company in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 45 → 41 (-4)
24% less capital invested
Capital invested by funds: $70.4M → $53.9M (-$16.6M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$2.17M |
| 2 |
ONB
Old National Bancorp
Evansville,
Indiana
|
+$161K |
| 3 |
Renaissance Technologies
New York
|
+$122K |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$67.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$217K |
| 2 |
Two Sigma Advisers
New York
|
-$149K |
| 3 |
Millennium Management
New York
|
-$141K |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$133K |
| 5 |
Two Sigma Investments
New York
|
-$118K |
LJPC Hedge Fund Activity: Q2 2022 in Review
41 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2022, worth a combined $53.9M — down 24% from $70.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LJPC and 2 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was HealthInvest Partners, adding an estimated $2.17M. The largest seller was Citadel Advisors, exiting entirely with an estimated $217K sold.
- 41 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2022, down from 45 in Q1 2022.
- Funds reported $53.9M of La Jolla Pharmaceutical Company stock for Q2 2022, down 24% quarter-over-quarter.
- 2 funds opened new La Jolla Pharmaceutical Company positions in Q2 2022 and 6 closed out, a net change of -4 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2022 was HealthInvest Partners, an estimated $2.17M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2022 was Citadel Advisors, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2022.